Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251596 | 1.00 | TSHR (0.43) | TSHRCES1ORAI1ORAI2ORAI3 | |
| SCHEMBL8912020 | 0.82 | TSHR (0.43) | TSHRCES1ORAI1ORAI2ORAI3 | |
| SCHEMBL11095966 | 0.82 | TSHR (0.43) | TSHRCES1ORAI1ORAI2ORAI3 | |
| SCHEMBL1751341 | 0.82 | TSHR (0.43) | TSHRCES1ORAI1ORAI2ORAI3 | |
| SCHEMBL20477815 | 0.81 | TSHR (0.38) | TSHRCES1ORAI1ORAI2ORAI3 | |
| SCHEMBL24785772 | 0.81 | SIGMAR1 (0.41) | MAOBMAOA | |
| SCHEMBL24592277 | 0.81 | SIGMAR1 (0.41) | MAOBMAOA | |
| SCHEMBL23343022 | 0.81 | TDP1 (0.34) | CYP2A6NPC1 | |
| SCHEMBL24786222 | 0.79 | CYP2D6 (0.35) | HTR2CHTR2AMAPK14DRD2DRD3 | |
| SCHEMBL24592163 | 0.79 | CHRM2 (0.33) | HTR2CHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354381-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-12 | — | — | US | claimed |
| EP-3609885-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | Centre National De La Recherche Scientifique (FR) | 2020-02-19 | — | — | EP | claimed |
| WO-2018172543-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-09-27 | — | — | WO | claimed |
| US-20230286920-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-09-14 | — | — | US | disclosed |
| US-11673865-B2 | Cyclooctynes for click chemistry | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20220402876-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-12-22 | — | — | US | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| US-11377424-B1 | Cyclooctynes for click chemistry | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022103983-A9 | FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20170253699-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170240703-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9587070-B2 | Polymeric structures containing strained cycloalkyne functionality for post-fabrication azidealkyne cycloaddition functionalization | THE UNIVERSITY OF AKRON | 2017-03-07 | — | — | US | disclosed |
| US-9227943-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150126706-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8940859-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354381-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | DYRK4, TALDO1, DYRK3 | TSHR 1499/4885CES1 4203/4885ORAI1 1322/4885 |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | TSHR 2283/4885CES1 2397/4885ORAI1 1674/4885 |
| US-11377424-B1 | Cyclooctynes for click chemistry | CBR3, CYCS, APOBEC3C | TSHR 2545/4885CES1 3175/4885ORAI1 2774/4885 |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | TSHR 2283/4885CES1 2397/4885ORAI1 1674/4885 |
| US-20230286920-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | CBR3, CYCS, APOBEC3C | TSHR 2545/4885CES1 3175/4885ORAI1 2774/4885 |
| US-20150126706-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | TSHR 2283/4885CES1 2397/4885ORAI1 1674/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | TSHR 1841/4885CES1 2101/4885ORAI1 4184/4885 |
| US-20220402876-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | CBR3, CYCS, APOBEC3C | TSHR 2545/4885CES1 3175/4885ORAI1 2774/4885 |
| US-11673865-B2 | Cyclooctynes for click chemistry | CBR3, CYCS, APOBEC3C | TSHR 2545/4885CES1 3175/4885ORAI1 2774/4885 |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | ERBB2, BRD2, PA2G4 | TSHR 447/4885CES1 4257/4885ORAI1 3689/4885 |
| US-20170240703-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | TSHR 3260/4885CES1 1767/4885ORAI1 4205/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | TSHR 2286/4885CES1 2067/4885ORAI1 4319/4885 |
| US-20170253699-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | TSHR 3260/4885CES1 1767/4885ORAI1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.